Daily SMS reminders for asthma treatment adherence: A comment on Strandbygaard et al.  by Razykov, Ilya et al.
Respiratory Medicine (2010) 104, 1234e1235ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedLETTER TO THE EDITORDaily SMS reminders for asthma treatment adherence:
A comment on Strandbygaard et al.Recently, Strandbygaard et al.1 investigated the effect of
daily Short Message Service (SMS) reminders on patients’
adherence to asthma treatment. They collected baseline
adherence data on 26 patients with a positive history of
asthma and a positive methacholine challenge test, then
randomized them to receive either daily SMS reminders to
take their anti-asthmatic medication (NZ 12) or usual care
(NZ 14). The authors found a statistically significant
difference in mean adherence rates after 12 weeks
between the 10 patients in the intervention group and the
12 patients in the control group who completed the study.
Based on this, they concluded that a daily SMS reminder
creates “a higher awareness of asthma control and treat-
ment, and by implementing this awareness in a patient’s
daily routine the adherent behaviour is improved.”
We agree with the authors that SMS reminders may be an
inexpensive and highly feasible way to improve adherence
to asthma treatment. We also agree that the limited
sample size used in the study requires that the findings are
replicated before unambiguous conclusions are drawn.
Recent publications on the limitations of research with
small sample sizes and of treatment adherence in asthma
may be useful in further understanding the importance of
replication of these findings.
In his widely-cited article Why Most Published Research
Findings Are False, Ioannidis2 demonstrated that published
randomized controlled trials with insufficient statistical
power reflect false positive findings over 80% of the time.
This is largely because of publication bias in which positive
trials with small sample sizes are much more likely to be
published than negative trials with small sample sizes. Many
published trials with small sample sizes find positive results
even when the null hypothesis is true due to sampling
oddities that sometimes occur in the context of very small
sample sizes. Strandbygaard et al. graciously shared the
data from their study with us. At baseline, adherence was
approximately 80% in the treatment and control groups.
Based on the data provided by Strandbygaard et al., the
standard deviation of the change in rate of adherence wasDOI of original article: 10.1016/j.rmed.2010.03.034.
0954-6111/$ - see front matter ª 2009 Published by Elsevier Ltd.
doi:10.1016/j.rmed.2009.12.01816.2% for the 22 patients who completed the study. Given
this, the power to detect a difference between the inter-
vention and control groups in change in rate of adherence
of even 10% was only 0.28, which is far below standard
expectations for power of 70% to 80%.
Furthermore, Strandbygaard et al. did not find that
adherence increased substantially in the treatment group.
Based on their original data, only one patient in the inter-
vention group improved by at least 10%. Indeed, improve-
ment in adherence was not significant in the intervention
group, with the mean adherence rising only by 3.6%
(PZ 0.52). Instead, there was a dramatic and unexpected
drop in the adherence rate in the control group of 14.2%
(PZ 0.01). A recent study using data from a large adminis-
trative database showed that a substantial proportion of
patients with asthma do not take prescribed medication
persistently and that many take it for relatively short
periods.3 However, that study did not show that the overall
rate of medication use in the population changes over time,
aswas the case in the control group studied by Strandbygaard
et al. More directly relevant, a review of 10 trials on adher-
ence to anti-asthma medication described in a recent
systematic review4 shows that adherence rates do not typi-
cally drop precipitously among usual care control patients in
trial settings as occurred in the study by Strandbygaard et al.
Improving adherence is an important objective, and we
applaud efforts by Strandbygaard et al. and others to find
solutions to the problem of poor treatment adherence in
asthma. We hope that Strandbygaard et al. will continue to
test the SMS intervention with a larger sample of patients in
order to better understand whether or not it will likely
produce tangible benefits to patients.
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